Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity
Open accessPublished version of a preprint
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Histone H3 lysine 9 dimethylation and trimethylation (H3K9me2/3) are prevalent in human genomes, especially in heterochromatin and specific euchromatic genes. Methylation of H3K9 is modulated by enzymes such as SUV39H1, SUV39H2, SETDB1, SETDB2, and EHMT1/2, which influence cancer progression. This study reveals differential expression of these six H3K9 methyltransferases in tumors, with SUV39H1, SUV39H2, and SETDB1 showing significant links to cancer phenotypes. We developed the "H3K9me3 MtSig" (H3K9me3 methyltransferases signature) based on these findings. H3K9me3 MtSig is unique to various tumors, with prognostic significance and associations with key signaling pathways, especially in glioblastoma (GBM). Elevated H3K9me3 MtSig was observed in GBM samples, correlating with the G2/M cell cycle and reduced immune responses. H3K9me3-mediated repetitive sequence silencing by H3K9me3 MtSig contributed to these phenotypes, and inhibiting H3K9me3 MtSig in patient-derived GBM cells suppressed proliferation and increased immune responses. H3K9me3 MtSig serves as an independent prognostic factor and potential therapeutic target.
Overview
CoChat Summary
TL;DR
This multi-omics study defines an H3K9me3 methyltransferases signature (H3K9me3 MtSig) from SUV39H1, SUV39H2, and SETDB1 and links it to poor prognosis, G2/M checkpoint activation, and reduced immune responses, especially in glioblastoma (GBM). In patient-derived GBM cells, H3K9me3 MtSig maintains H3K9me3 at repetitive elements, and its inhibition suppresses proliferation while inducing immune-response genes.
Key findings
- Across cancers, SUV39H1, SUV39H2, and SETDB1 showed correlated expression and prognostic relevance; high expression was associated with poorer survival in GBM, SARC, LIHC, and BRCA with hazard ratios of 1.5 to 2.2, and SUV39H1/SUV39H2/SETDB1 high expression was associated with poorer prognosis with hazard ratios of 1.3 to 1.8 in GBM and KIRP.
- H3K9me3 MtSig was positively correlated with the G2/M checkpoint (pan-cancer R = 0.63, P < 0.001; GBM R = 0.81, P < 0.001) and negatively correlated with immune responses (pan-cancer R = -0.16, P < 0.001; GBM R = -0.6, P < 0.001).
- In GBM cells, knockdown of SUV39H1, SUV39H2, and SETDB1 reduced tumorsphere formation; SUV39H1 knockdown reduced H3K9me3 enrichment at repetitive elements, downregulated G2/M checkpoint genes, upregulated immune-response genes, and caused G2/M arrest.
- Drug susceptibility screening linked elevated H3K9me3 MtSig to increased sensitivity to compounds including GDC-0879, vemurafenib, MK-0752, BRD-K33199242, and PLX-4720 by CTRP2.0, and EPZ-5676, oxymatrine, ganetespib, rubitecan, dirithromycin, and simvastatin by PRISM.
Methods
- Integrated multi-omic analyses of TCGA data across 33 cancer types, with paired tumor-normal analyses in 20 cancer types, including expression, survival, SNV, CNV, and DNA methylation; H3K9me3 MtSig was calculated by ssGSEA using SUV39H1, SUV39H2, and SETDB1.
- Pathway and single-cell analyses used GSEA and the Extended GBmap dataset, comprising 16 datasets from 110 GBM patients and over 330,000 cells.
- Experimental validation used patient-derived GBM cells (GSC3565 and public GSC23 ChIP-seq), with H3K9me3 ChIP-seq, RNA-seq, qPCR, tumorsphere assays, cell cycle analysis, immunohistochemistry, immunofluorescence, and H3K9M plasmid-mediated H3K9me3 depletion; clinical prediction models used TCGA GBM and CGGA GBM data, and drug susceptibility used CTRP2.0 and PRISM.
Limitations
- The paper states that further studies are necessary to validate and explore the immunotherapy-response associations in other cancer types, and that the drug-sensitivity findings require additional research and validation.
- The paper states that future studies should investigate the specific molecular mechanisms connecting H3K9me3 MtSig with drug sensitivity and the detailed mechanisms linking H3K9 methylation, immune response pathways, and the tumor microenvironment.
- Evident from the text: the experimental validation is largely cell-based in patient-derived GBM cells/GSCs, with no in vivo animal model reported in the Methods; the clinical prediction model is developed and revalidated retrospectively using TCGA and CGGA data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
14 Valid · 2 Not valid · 6 Not checked · 69 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified a robust correlation between H3K9me3 MtSig and both G2/M checkpoint and immune responses across diverse cancers (Supplementary Fig. 9A–E).”
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Results > H3K9me3 methyltransferases signature (H3K9me3 MtSig) and regulated pathways in cancers
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, SUV39H1 exhibits a pattern opposite to other H3K9 methyltransferase genes in BLCA and STAD (P < 0.05; Fig. 2D).”
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Results > Genetic and epigenetic alterations of H3K9 methyltransferases genes
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Drug susceptibility screening revealed a significant positive correlation between elevated H3K9me3 MtSig and increased sensitivity to various compounds.”
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Discussion
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the majority of tumors, H3K9me3 MtSig was significantly upregulated compared to the normal, except for THCA (Fig. 3A).”
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Results > H3K9me3 methyltransferases signature (H3K9me3 MtSig) and regulated pathways in cancers
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The H3K9 methyltransferase genes displayed distinct CNV patterns, with similar frequencies of 6% to 12% observed for SUV39H1 and SUV39H2 across major cancer types (Fig. 2B).”
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Results > Genetic and epigenetic alterations of H3K9 methyltransferases genes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
44 more claims
Create a free account to see all 91 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Results > Clinical prediction model incorporating H3K9me3 MtSig for GBM
“Calibration curves for 1-year, 2-year, and 3-year survival rates closely aligned with the standard curve, affirming the accuracy of our network score curve in approximating actual survival probabilities (Fig. 7C).”
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Results > Clinical prediction model incorporating H3K9me3 MtSig for GBM
“D Calibration of the nomogram for predicting 1-year, 2-year, and 3-year outcomes, showing the consistency between predicted and observed results.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Results > Clinical prediction model incorporating H3K9me3 MtSig for GBM
“The time-dependent concordance index demonstrated strong model consistency when combining H3K9me3 MtSig with clinical prognostic factors (Fig. 7D).”
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Results > Clinical prediction model incorporating H3K9me3 MtSig for GBM
“E Concordance index showing measure of concordance of predictor with survival of patients.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Results > H3K9me3 MtSig regulates repetitive sequence silencing in GBM
“For (J) and (K), data are presented as mean ± SEM (n = 3).”
§ Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity > Results > H3K9me3 MtSig regulates repetitive sequence silencing in GBM
“D The working model showing the signal cascade between H3K9me3 MtSig, H3K9me3, repeat elements, cell cycle regulation (G2/M checkpoint), and immune responses in the context of GBM.”
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data
(2021) · doi:10.1016/j.xinn.2021.100141 · Cited by 12,455
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 4,935
Next-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394 · cited 1×
“The expression pro fi le data for human cancer cell lines were obtained from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) project (https:// portals.broadinstitute.org/ccle/) 46 .”
Cited by
Wang, S., Hu, D., Wang, R., Huang, J., & Wang, B. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01027-z · Cited by 26
Giannopoulou, A.-I., Skouras, P., Sarantis, P., Armoundas, A. A., Palamaris, K., Gargalionis, A. N., Sepsa, A., Boviatsis, E. I., Κalamatianos, T., Stranjalis, G., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00754 · Cited by 5
Kundu, S., Akhtar, A. R., Kumar, A., & Sharma, A. K. (2026) · Scientific Reports · doi:10.1038/s41598-026-44020-7 · Cited by 4
Li, Y., Wu, L., Shi, J., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102929
Choudhary, A., Kumar, P., Kashyap, S., Patidar, V., Kumar, A. C. S., & Munshi, A. (2026) · Epigenomics · doi:10.1080/17501911.2026.2698002
Metadata
- Authors
- Xie, Q., Du, Y., Ghosh, S., Rajendran, S., Cohen-Gadol, A. A., Baizabal, J.-M., Nephew, K. P., Han, L., & Shen, J.
- Affiliations
- Indiana University School of Medicine (US)
- Indiana University Bloomington (US)
- Indiana University Health (US)
- Indiana University Indianapolis (US)
- Corresponding author
- Han, Leng
- Shen, Jia
- ORCID
- Venue
- NPJ Precision Oncology
- Published
- 2025-03-20
- Volume
- 9
- Issue
- 1
- Pages
- 78-78
- ISSN
- 2397-768X (ISSN-L)
- PMC
- PMC11926169
- OpenAlex
- W4408666086
- Cited by
- 10
- References
- 49
- Citations by year
- 2026: 4 · 2025: 6
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- npj Precision Oncology (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
- Funders
- U.S. Department of Health & Human Services | National Institutes of Health (R01HG011633, R01CA262623)
- This study received funding from the Indiana University School of Medicine Start-Up Fund (to J. Shen) and the Schwarz Family and Friends Cancer Research Fund (to J. Shen).
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Keywords
- glioblastoma, H3K9me3, histone methyltransferase, SUV39H1, SUV39H2, SETDB1, SETDB2, prognostic factors, antitumor immunity, G2/M phase, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity. https://app.cochat.ai/papers/10.1038/s41698-025-00829-5
- The paper
- Xie, Q., Du, Y., Ghosh, S., Rajendran, S., Cohen-Gadol, A. A., Baizabal, J.-M., Nephew, K. P., Han, L., & Shen, J. (2025). Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity. NPJ Precision Oncology. https://doi.org/10.1038/s41698-025-00829-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.